<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333956</url>
  </required_header>
  <id_info>
    <org_study_id>11043</org_study_id>
    <nct_id>NCT01333956</nct_id>
  </id_info>
  <brief_title>Effects of Pregabalin on Pain After Total Knee Arthroplasty</brief_title>
  <official_title>Effects of Pregabalin on Pain After Total Knee Arthroplasty: A Randomized, Controlled, Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <brief_summary>
    <textblock>
      Total knee arthroplasty can cause severe postoperative pain, and patients typically receive
      oral opioid analgesics for over 2 weeks. Side effects of pain management may impair
      participation in physical therapy and diminish patient satisfaction. Anecdotally, it seems
      that pregabalin is very helpful to patients after total knee arthroplasty. However,
      pregabalin can have side effects. It is not clear how much pregabalin to prescribe. Low doses
      may not be effective, but use of high doses may increase the incidence and severity of side
      effects.The purpose of this study is to determine which dosage of pregabalin is the most
      effective at reducing pain after knee surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>2 weeks postoperatively</time_frame>
    <description>Pain assessment scale (Numeric Rating Scale) (0=no pain; 10=worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related Symptom Distress Score</measure>
    <time_frame>2 weeks postoperatively</time_frame>
    <description>Opioid-Related Symptom Distress score (ORSDS) measured at POD1 and POD14. The ORSDS is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores. (0=low; 4=high).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessed Sedation and Confusion</measure>
    <time_frame>1 day postoperatively</time_frame>
    <description>Self-assessed sedation and confusion (POD1). Confusion Assessment Method (CAM score) (pre-operative and on POD1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale (NRS)</measure>
    <time_frame>3 months</time_frame>
    <description>NRS Pain (pre-operative, POD1, POD3, 2 weeks, 3 months, at orthopedic visits). Neuropathic pain incidence: Leeds assessment of neuropathic symptoms and signs (LANSS) score (3 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain</measure>
    <time_frame>3 months</time_frame>
    <description>Neuropathic pain incidence: Leeds assessment of neuropathic symptoms and signs (LANSS) score (3 months). Scale of 0 to 24. Higher values represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Usage</measure>
    <time_frame>3 months</time_frame>
    <description>Opioid Usage (POD1, POD 3, 2 weeks, 3 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Satisfaction with pain management (1-10 scale; 1 = very dissatisfied, 10 = very satisfied)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Primary Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 0mg of pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 50mg</intervention_name>
    <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
    <arm_group_label>50mg Arm</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 100mg</intervention_name>
    <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
    <arm_group_label>100mg Arm</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
    <arm_group_label>150mg Arm</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with osteoarthritis scheduled for primary tricompartmental total knee
             arthroplasty with a participating surgeon

          -  Age 18 to 80 years old

          -  Planned use of regional anesthesia

          -  Ability to follow study protocol

          -  English speaking (primary outcome obtained via telephone call and secondary outcomes
             include questionnaires validated in English only)

          -  Patients planning on being discharged home or to a rehabilitation center that has
             agreed to participate

        Exclusion Criteria:

          -  Patients younger than 18 years old and older than 80

          -  Patients intending to receive general anesthesia

          -  Allergy or intolerance to one of the study medications

          -  Patients with an ASA of IV

          -  Patients with hepatic (liver) failure

          -  Patients with chronic renal (kidney) failure (Defined as estimated creatinine
             clearance &lt; 30 mL/min, based on recommendation that total daily pregabalin dose be
             reduced to 150 mg with Clcr &lt; 30 mL/min, CLcr=[(140-age (years)] x weight (kg)x0.85
             (for female patients)/[72xserum creatinine (mg/dL)])

          -  Patients with difficult to manage diabetes mellitus, including insulin-dependence

          -  Chronic gabapentin/pregabalin use (regular use for longer than 3 months)

          -  Chronic opioid use (taking opioids for longer than 3 months)

          -  Patients with major prior ipsilateral open knee surgery.

          -  Chronic neurontin/lyrica use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques T YaDeau, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2011</study_first_submitted>
  <study_first_submitted_qc>April 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <results_first_submitted>July 21, 2015</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2016</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose.</description>
        </group>
        <group group_id="P2">
          <title>50mg Arm</title>
          <description>Patients will receive 50mg of pregabalin per dose.</description>
        </group>
        <group group_id="P3">
          <title>100mg Arm</title>
          <description>Patients will receive 100mg of pregabalin per dose.</description>
        </group>
        <group group_id="P4">
          <title>150mg Arm</title>
          <description>Patients will receive 150mg of pregabalin per dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to complete study procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="B2">
          <title>50mg Arm</title>
          <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="B3">
          <title>100mg Arm</title>
          <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="B4">
          <title>150mg Arm</title>
          <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="9.8"/>
                    <measurement group_id="B2" value="66.8" spread="6.3"/>
                    <measurement group_id="B3" value="65.1" spread="7.1"/>
                    <measurement group_id="B4" value="67.7" spread="8.1"/>
                    <measurement group_id="B5" value="66.3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m ^ 2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="5"/>
                    <measurement group_id="B2" value="32" spread="6"/>
                    <measurement group_id="B3" value="32" spread="6"/>
                    <measurement group_id="B4" value="30" spread="7"/>
                    <measurement group_id="B5" value="31.5" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain</title>
        <description>Pain assessment scale (Numeric Rating Scale) (0=no pain; 10=worst pain imaginable).</description>
        <time_frame>2 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain</title>
          <description>Pain assessment scale (Numeric Rating Scale) (0=no pain; 10=worst pain imaginable).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>POD14 Pain score with flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2.3"/>
                    <measurement group_id="O2" value="4.8" spread="2.1"/>
                    <measurement group_id="O3" value="4.5" spread="2.4"/>
                    <measurement group_id="O4" value="4.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD14 Pain score with ambulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.0"/>
                    <measurement group_id="O2" value="3.8" spread="1.6"/>
                    <measurement group_id="O3" value="3.5" spread="1.8"/>
                    <measurement group_id="O4" value="3.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD14 Pain score at rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.3"/>
                    <measurement group_id="O2" value="2.9" spread="2.0"/>
                    <measurement group_id="O3" value="2.8" spread="1.8"/>
                    <measurement group_id="O4" value="2.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid-Related Symptom Distress Score</title>
        <description>Opioid-Related Symptom Distress score (ORSDS) measured at POD1 and POD14. The ORSDS is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores. (0=low; 4=high).</description>
        <time_frame>2 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid-Related Symptom Distress Score</title>
          <description>Opioid-Related Symptom Distress score (ORSDS) measured at POD1 and POD14. The ORSDS is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores. (0=low; 4=high).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ORSDS POD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".4" lower_limit=".2" upper_limit=".7"/>
                    <measurement group_id="O2" value=".4" lower_limit=".2" upper_limit=".6"/>
                    <measurement group_id="O3" value=".5" lower_limit=".2" upper_limit=".7"/>
                    <measurement group_id="O4" value=".4" lower_limit=".2" upper_limit=".8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ORSDS POD14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".3" lower_limit=".1" upper_limit=".5"/>
                    <measurement group_id="O2" value=".3" lower_limit=".1" upper_limit=".5"/>
                    <measurement group_id="O3" value=".3" lower_limit=".1" upper_limit=".5"/>
                    <measurement group_id="O4" value=".3" lower_limit="0" upper_limit=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-assessed Sedation and Confusion</title>
        <description>Self-assessed sedation and confusion (POD1). Confusion Assessment Method (CAM score) (pre-operative and on POD1)</description>
        <time_frame>1 day postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-assessed Sedation and Confusion</title>
          <description>Self-assessed sedation and confusion (POD1). Confusion Assessment Method (CAM score) (pre-operative and on POD1)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness POD1 [ORSDS]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="37.9"/>
                    <measurement group_id="O3" value="55.2"/>
                    <measurement group_id="O4" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea POD1 [ORSDS]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="44.8"/>
                    <measurement group_id="O4" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numeric Rating Scale (NRS)</title>
        <description>NRS Pain (pre-operative, POD1, POD3, 2 weeks, 3 months, at orthopedic visits). Neuropathic pain incidence: Leeds assessment of neuropathic symptoms and signs (LANSS) score (3 months)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Rating Scale (NRS)</title>
          <description>NRS Pain (pre-operative, POD1, POD3, 2 weeks, 3 months, at orthopedic visits). Neuropathic pain incidence: Leeds assessment of neuropathic symptoms and signs (LANSS) score (3 months)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preop NRS Pain Score with Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.7" upper_limit="6"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.3" upper_limit="6.5"/>
                    <measurement group_id="O3" value="3.9" lower_limit="2.8" upper_limit="5.1"/>
                    <measurement group_id="O4" value="5.7" lower_limit="4.4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD1 NRS Pain Score with Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.8" upper_limit="4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="2.7" lower_limit="1.8" upper_limit="3.3"/>
                    <measurement group_id="O4" value="2.5" lower_limit="1.2" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD3 NRS Pain Score with Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.8" upper_limit="4.8"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.5" upper_limit="5.2"/>
                    <measurement group_id="O3" value="3.6" lower_limit="2.8" upper_limit="4.7"/>
                    <measurement group_id="O4" value="4.3" lower_limit="3.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD14 NRS Pain Score with Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.4" upper_limit="5"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.2" upper_limit="5.6"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.7" upper_limit="5.4"/>
                    <measurement group_id="O4" value="4.2" lower_limit="3.2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months NRS Pain Score with Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1.9" lower_limit=".9" upper_limit="2.7"/>
                    <measurement group_id="O3" value="1.7" lower_limit=".7" upper_limit="1.8"/>
                    <measurement group_id="O4" value="1.8" lower_limit=".9" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropathic Pain</title>
        <description>Neuropathic pain incidence: Leeds assessment of neuropathic symptoms and signs (LANSS) score (3 months). Scale of 0 to 24. Higher values represent worse outcomes.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropathic Pain</title>
          <description>Neuropathic pain incidence: Leeds assessment of neuropathic symptoms and signs (LANSS) score (3 months). Scale of 0 to 24. Higher values represent worse outcomes.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Usage</title>
        <description>Opioid Usage (POD1, POD 3, 2 weeks, 3 months)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Usage</title>
          <description>Opioid Usage (POD1, POD 3, 2 weeks, 3 months)</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preop Total Opioid Use (mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="20"/>
                    <measurement group_id="O3" value="17" lower_limit="15" upper_limit="19"/>
                    <measurement group_id="O4" value="18" lower_limit="16" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD 1 Total Opioid Use (mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="40" upper_limit="63"/>
                    <measurement group_id="O2" value="46" lower_limit="35" upper_limit="57"/>
                    <measurement group_id="O3" value="57" lower_limit="41" upper_limit="73"/>
                    <measurement group_id="O4" value="45" lower_limit="35" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD 2 Total Opioid Use (mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="57" upper_limit="85"/>
                    <measurement group_id="O2" value="60" lower_limit="50" upper_limit="70"/>
                    <measurement group_id="O3" value="63" lower_limit="47" upper_limit="79"/>
                    <measurement group_id="O4" value="55" lower_limit="43" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD 3 Total Opioid Use (mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="43" upper_limit="67"/>
                    <measurement group_id="O2" value="60" lower_limit="50" upper_limit="70"/>
                    <measurement group_id="O3" value="40" lower_limit="30" upper_limit="50"/>
                    <measurement group_id="O4" value="36" lower_limit="30" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD 14 Total Opioid Use (mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="30" upper_limit="50"/>
                    <measurement group_id="O2" value="36" lower_limit="25" upper_limit="45"/>
                    <measurement group_id="O3" value="40" lower_limit="30" upper_limit="50"/>
                    <measurement group_id="O4" value="45" lower_limit="25" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months Total Opioid Use (mg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="4" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>Satisfaction with pain management (1-10 scale; 1 = very dissatisfied, 10 = very satisfied)</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O2">
            <title>50mg Arm</title>
            <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O3">
            <title>100mg Arm</title>
            <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
          <group group_id="O4">
            <title>150mg Arm</title>
            <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction</title>
          <description>Satisfaction with pain management (1-10 scale; 1 = very dissatisfied, 10 = very satisfied)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="8" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O3" value="8" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O4" value="8" lower_limit="6" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Patients will receive 0mg of pregabalin
Placebo: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="E2">
          <title>50mg Arm</title>
          <description>Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 50mg: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="E3">
          <title>100mg Arm</title>
          <description>Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 100mg: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
        <group group_id="E4">
          <title>150mg Arm</title>
          <description>Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Pregabalin 150mg: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jacques YaDeau</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>212-606-1206</phone>
      <email>yadeauj@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

